Neurocrine Biosciences (NBIX) Cash from Financing Activities (2010 - 2026)

Neurocrine Biosciences has reported Cash from Financing Activities for 17 years, with the latest figure at -$86.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 26.97% year-over-year to -$86.1 million; the trailing twelve-month figure through Mar 2026 stood at -$6.5 million (up 99.04% YoY), and the FY2025 full-year result was -$38.3 million, up 92.13% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$86.1 million, down from $37.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $69.9 million in Q1 2024, with the low at -$293.0 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged -$45.9 million across 5 years, with a median of $8.2 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 1266.67% — and 2024, when it plunged 10203.45%.
• Neurocrine Biosciences' Cash from Financing Activities stood at $24.6 million in 2022, then soared by 43.9% to $35.4 million in 2023, then plunged by 919.21% to -$290.0 million in 2024, then surged by 112.86% to $37.3 million in 2025, then tumbled by 330.83% to -$86.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$86.1 million (Q1 2026), $37.3 million (Q4 2025), and $45.6 million (Q3 2025), per Business Quant data.